In silico drug discovery of melatonin receptor ligands with therapeutic potential

References

• Lerner AB, Case JD, and Takahashi Y, et al. Isolation of melatonin, the pineal gland factor that lightens melanocytes. J Am Chem Soc. 1958;80(10):2587.
   Web of Science ®Google Scholar
• Zhao D, Yu Y, and Shen Y, et al. Melatonin synthesis and function: evolutionary history in animals and plants. Front Endocrinol (Lausanne). 2019;17(10):249.
   Google Scholar
• Hardeland R, Cardinali DP, and Srinivasan V, et al. Melatonin–a pleiotropic, orchestrating regulator molecule. Prog Neurobiol. 2011;93(3):350.
   PubMed Web of Science ®Google Scholar
• Liu L, Labani N, and Cecon E, et al. Melatonin target proteins: too many or not enough? Front Endocrinol. 2019;10:791.
   PubMed Web of Science ®Google Scholar
• Reiter RJ, Tan D-X, and Rosales-Corral S, et al. The universal nature, unequal distribution and antioxidant functions of melatonin and its derivatives. Mini Rev Med Chem. 2013;13(3):373–384.
   PubMed Web of Science ®Google Scholar
• Dubocovich ML, Delagrange P, and Krause DN, et al. International union of basic and clinical pharmacology. LXXV. nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors. Pharmacol Rev. 2010;62(3):343–380.
   PubMed Web of Science ®Google Scholar
• Cecon E, Oishi A, and Jockers R. Melatonin receptors: molecular pharmacology and signalling in the context of system bias. Br J Pharmacol. 2018;175(16):3263–3280.
   PubMed Web of Science ®Google Scholar
• Jockers R, Delagrange P, and Dubocovich ML, et al. Update on melatonin receptors: IUPHAR review 20. Br J Pharmacol. 2016;173(18):2702–2725.
   PubMed Web of Science ®Google Scholar
• Liu J, Clough SJ, and Hutchinson AJ, et al. MT 1 and MT 2 melatonin receptors: a therapeutic perspective. Annu Rev Pharmacol Toxocol. 2016;56(1):361–383.
   PubMed Web of Science ®Google Scholar
• Hardeland R, Poeggeler B, Srinivasan V, et al. Melatonergic drugs in clinical practice. Arzneimittelforschung. 2008;58(1):1–10.
   PubMed Web of Science ®Google Scholar
• Dubocovich ML, Masana MI, and Iacob S, et al. Melatonin receptor antagonists that differentiate between the human mel1a and mel1b recombinant subtypes are used to assess the pharmacological profile of the rabbit retina ML1 presynaptic heteroreceptor. Naunyn Schmiedebergs Arch Pharmacol. 1997;355(3):365–375.
   PubMed Web of Science ®Google Scholar
• Zlotos DP, Jockers R, and Cecon E, et al. MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential. J Med Chem. 2014;57(8):3161–3185.
   PubMed Web of Science ®Google Scholar
• Dubocovich ML, Markowska M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine. 2005;27(2):101–110.
   PubMed Web of Science ®Google Scholar
• Rivara S, Pala D, and Bedini A, et al. Therapeutic uses of melatonin and melatonin derivatives: a patent review (2012 – 2014). Expert Opin Ther Pat. 2015;25(4):425–441.
   PubMed Web of Science ®Google Scholar
• Johansson LC, Stauch B, and McCorvy JD, et al. XFEL structures of the human MT2 melatonin receptor reveal the basis of subtype selectivity. Nature. 2019;569(7755):289–292.
   PubMed Web of Science ®Google Scholar
• Stauch B, Johansson LC, and McCorvy JD, et al. Structural basis of ligand recognition at the human MT1 melatonin receptor. Nature. 2019;569(7755):284–288.
   PubMed Web of Science ®Google Scholar
• Boutin JA, Witt-Enderby PA, and Sotriffer C, et al. Melatonin receptor ligands: a pharmaco-chemical perspective. J Pineal Res. 2020;69(3):e12672.
   PubMed Web of Science ®Google Scholar
• Wallez V, Durieux-Poissonnier S, and Chavatte P, et al. Synthesis and structure-affinity-activity relationships of novel benzofuran derivatives as MT2 melatonin receptor selective ligands. J Med Chem. 2002;45(13):2788–2800.
   PubMed Web of Science ®Google Scholar
• Yous S, Andrieux J, and Howell HE, et al. Novel naphthalenic ligands with high affinity for the melatonin receptor. J Med Chem. 1992;35(8):1484–1486.
   PubMed Web of Science ®Google Scholar
• Depreux P, Lesieur D, and Mansour HA, et al. Synthesis and structure-activity relationships of novel naphthalenic and bioisosteric related amidic derivatives as melatonin receptor ligands. J Med Chem. 1994;37(20):3231–3239.
   PubMed Web of Science ®Google Scholar
• Mésangeau C, Fraise M, and Delagrange P, et al. Preparation and pharmacological evaluation of a novel series of 2-(phenylthio)benzo[b]thiophenes as selective MT2 receptor ligands. Eur J Med Chem. 2011;46(5):1835–1840.
   PubMed Web of Science ®Google Scholar
• Fourmaintraux E, Depreux P, and Lesieur D, et al. Tetrahydronaphthalenic derivatives as new agonist and antagonist ligands for melatonin receptors. Bioorg Med Chem. 1998;6(1):9–13.
   PubMed Web of Science ®Google Scholar
• Uchikawa O, Fukatsu K, and Tokunoh R, et al. Synthesis of a novel series of tricyclic indan derivatives as melatonin receptor agonists. J Med Chem. 2002;45(19):4222–4239.
   PubMed Web of Science ®Google Scholar
• Li P-K, Chu G-H, and Gillen ML, et al. Synthesis and receptor binding studies of quinolinic derivatives as melatonin receptor ligands. Bioorg Med Chem Lett. 1997;7(17):2177–2180.
   Web of Science ®Google Scholar
• Garratt PJ, Travard S, and Vonhoff S, et al. Mapping the melatonin receptor. 4. Comparison of the binding affinities of a series of substituted phenylalkyl amides. J Med Chem. 1996;39(9):1797–1805.
   PubMed Web of Science ®Google Scholar
• Rivara S, Lodola A, and Mor M, et al. N-(substituted-anilinoethyl)amides: design, synthesis, and pharmacological characterization of a new class of melatonin receptor ligands. J Med Chem. 2007;50(26):6618–6626.
   PubMed Web of Science ®Google Scholar
• Carocci A, Catalano A, and Lovece A, et al. Design, synthesis, and pharmacological effects of structurally simple ligands for MT1 and MT2 melatonin receptors. Bioorg Med Chem. 2010;18(17):6496–6511.
   PubMed Web of Science ®Google Scholar
• Teh MT, and Sugden D. Comparison of the structure-activity relationships of melatonin receptor agonists and antagonists: lengthening the N-acyl side-chain has differing effects on potency on Xenopus melanophores. Naunyn Schmiedebergs Arch Pharmacol. 1998;358(5):522–528.
   PubMed Web of Science ®Google Scholar
• Ballesteros JA, and Weinstein H. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. J Neurosci Methods. 1995;25(19):366–428.
   Google Scholar
• Leclerc V, Fourmaintraux E, and Depreux P, et al. Synthesis and structure-activity relationships of novel naphthalenic and bioisosteric related amidic derivatives as melatonin receptor ligands. Bioorg Med Chem. 1998;6(10):1875–1887.
   PubMed Web of Science ®Google Scholar
• Rami M, Landagaray E, and Ettaoussi M, et al. Novel conformationally constrained analogues of agomelatine as new melatoninergic ligands. Molecules. 2012;18(1):154–166.
   PubMed Web of Science ®Google Scholar
• de la Fuente Revenga M, Fernández-Sáez N, and Herrera-Arozamena C, et al. Novel N-acetyl bioisosteres of melatonin: melatonergic receptor pharmacology, physicochemical studies, and phenotypic assessment of their neurogenic potential. J Med Chem. 2015;58(12):4998–5014.
   PubMed Web of Science ®Google Scholar
• Kanayama T, Kubota H, and Matsumoto S, et al. Astellas Pharma Inc., assignee. Indolecarboxamide derivatives. European Patent EP2873660B1. 2016 Oct 26.
   Google Scholar
• Ferreira MA Jr, Azevedo H, and Mascarello A, et al. Discovery of ACH-000143: a novel potent and peripherally preferred melatonin receptor agonist that reduces liver triglycerides and steatosis in diet-induced obese rats. J Med Chem. 2021;64(4):1904–1929.
   PubMed Web of Science ®Google Scholar
• Faust R, Garratt PJ, and Jones R, et al. Mapping the melatonin receptor. 6. melatonin agonists and antagonists derived from 6H-isoindolo[2,1-a]indoles, 5,6-dihydroindolo[2,1-a]isoquinolines, and 6,7-dihydro-5H-benzo[c]azepino[2,1-a]indoles. J Med Chem. 2000;43(6):1050–1061.
   PubMed Web of Science ®Google Scholar
• Fisher SP, and Sugden D. Sleep-promoting action of IIK7, a selective MT2 melatonin receptor agonist in the rat. Neurosci Lett. 2009;457(2):93–96.
   PubMed Web of Science ®Google Scholar
• Alarma-Estrany P, Crooke A, and Aránzazu M, et al. Sympathetic nervous system modulates the ocular hypotensive action of MT2-melatonin receptors in normotensive rabbits. J Pineal Res. 2008;45(4):468–475.
   PubMed Web of Science ®Google Scholar
• Dortch-Carnes J, and Tosini G. Melatonin receptor agonist-induced reduction of SNP-released nitric oxide and cGMP production in isolated human non-pigmented ciliary epithelial cells. Exp Eye Res. 2013;107:1–10.
   PubMed Web of Science ®Google Scholar
• Crooke A, Guzman-Aranguez A, and Aránzazu M, et al. Effect of melatonin and analogues on corneal wound healing: involvement of Mt2 melatonin receptor. Curr Eye Res. 2015;40(1):56–65.
   PubMed Web of Science ®Google Scholar
• Navarro Gil FJ, Huete-Toral F, Crooke A, et al. Effect of melatonin and its analogs on tear secretion. J Pharmacol Exp Ther. 2019;371(1):186–190.
   PubMed Web of Science ®Google Scholar
• Descamps-François C, Yous S, and Chavatte P, et al. Design and synthesis of naphthalenic dimers as selective MT1 melatoninergic ligands. J Med Chem. 2003;46(7):1127–1129.
   PubMed Web of Science ®Google Scholar
• Sun L-Q, Chen J, and Takaki K, et al. Design and synthesis of benzoxazole derivatives as novel melatoninergic ligands. Bioorg Med Chem Lett. 2004;14(5):1197–1200.
   PubMed Web of Science ®Google Scholar
• Mésangeau C, Pérès B, and Descamps-François C, et al. Design, synthesis and pharmacological evaluation of novel naphthalenic derivatives as selective MT1 melatoninergic ligands. Bioorg Med Chem. 2010;18(10):3236–3426.
   Web of Science ®Google Scholar
• Di Giacomo B, Bedini A, and Spadoni G, et al. Synthesis and biological activity of new melatonin dimeric derivatives. Bioorg Med Chem. 2007;15(13):4643–4650.
   PubMed Web of Science ®Google Scholar
• Rivara S, Pala D, Lodola A, et al. MT1-selective melatonin receptor ligands: synthesis, pharmacological evaluation, and molecular dynamics investigation of N-{[(3-O-substituted)anilino]alkyl}amides. ChemMedChem. 2012;7(11):1954–1964.
   PubMed Web of Science ®Google Scholar
• Stein RM, Kang HJ, and McCorvy JD, et al. Virtual discovery of melatonin receptor ligands to modulate circadian rhythms. Nature. 2020;579(7800):609–614.
   PubMed Web of Science ®Google Scholar
• Jansen JM, Copinga S, and Gruppen G, et al. The high affinity melationin binding site probed with conformationally restricted ligand–I. pharmacophore and minireceptor models. Bioorg Med Chem. 1996;4(8):1321–1332.
   PubMed Web of Science ®Google Scholar
• Spadoni G, Balsamini C, and Diamantini G, et al. Conformationally restrained melatonin analogues: synthesis, binding affinity for the melatonin receptor, evaluation of the biological activity, and molecular modeling study. J Med Chem. 1997;40(13):1990–2002.
   PubMed Web of Science ®Google Scholar
• Morellato L, Lefas-Le Gall M, and Langlois M, et al. Synthesis of new N-(arylcyclopropyl)acetamides and N-(arylvinyl)acetamides as conformationally-restricted ligands for melatonin receptors. Bioorg Med Chem Lett. 2013;23(2):430–434.
   PubMed Web of Science ®Google Scholar
• Sun L-Q, Chen J, and Takaki K, et al. Design and synthesis of benzoxazole derivatives as novel melatoninergic ligands. Bioorg Med Chem Lett. 2004;14(5):1197–1200.
   PubMed Web of Science ®Google Scholar
• Rivara S, Diamantini G, and Di Giacomo B, et al. Reassessing the melatonin pharmacophore–enantiomeric resolution, pharmacological activity, structure analysis, and molecular modeling of a constrained chiral melatonin analogue. Bioorg Med Chem. 2006;14(10):3383–3391.
   PubMed Web of Science ®Google Scholar
• Mor M, Spadoni G, and Di Giacomo B, et al. Synthesis, pharmacological characterization and QSAR studies on 2-substituted indole melatonin receptor ligands. Bioorg Med Chem. 2001;9(4):1045–1057.
   PubMed Web of Science ®Google Scholar
• Spadoni G, Balsamini C, and Diamantini G, et al. 2-N-Acylaminoalkylindoles: design and quantitative structure −activity relationship studies leading to MT2-selective melatonin antagonists. J Med Chem. 2001;44(18):2900–2912.
   PubMed Web of Science ®Google Scholar
• Bedini A, Lucarini S, and Spadoni G, et al. Toward the definition of stereochemical requirements for MT2-selective antagonists and partial agonists by studying 4-phenyl-2-propionamidotetralin derivatives. J Med Chem. 2011;54(24):8362–8372.
   PubMed Web of Science ®Google Scholar
• Rivara S, Mor M, and Silva C, et al. Three-dimensional quantitative structure-activity relationship studies on selected MT1 and MT2 melatonin receptor ligands: requirements for subtype selectivity and intrinsic activity modulation. J Med Chem. 2003;46(8):1429–1439.
   PubMed Web of Science ®Google Scholar
• Rivara S, Lorenzi S, and Mor M, et al. Analysis of structure-activity relationships for MT2 selective antagonists by melatonin MT1 and MT2 receptor models. J Med Chem. 2005;48(12):4049–4060.
   PubMed Web of Science ®Google Scholar
• Lucini V, Pannacci M, and Scaglione F, et al. Tricyclic alkylamides as melatonin receptor ligands with antagonist or inverse agonist activity. J Med Chem. 2004;47(17):4202–4212.
   PubMed Web of Science ®Google Scholar
• Spadoni G, Bedini A, Diamantini G, et al. Synthesis, enantiomeric resolution, and structure-activity relationship study of a series of 10,11-dihydro-5H-dibenzo[a,d]cycloheptene MT 2 receptor antagonists. ChemMedChem. 2007;2(12):1741–1749.
   PubMed Web of Science ®Google Scholar
• Devavry S, Legros C, and Brasseur C, et al. Description of the constitutive activity of cloned human melatonin receptors hMT1 and hMT2 and discovery of inverse agonists. J Pineal Res. 2012;53(1):29–37.
   PubMed Web of Science ®Google Scholar
• Bedini A, Spadoni G, and Gatti G, et al. Design and synthesis of N-(3,3-diphenylpropenyl)alkanamides as a novel class of high-affinity MT2-selective melatonin receptor ligands. J Med Chem. 2006;49(25):7393–7403.
   PubMed Web of Science ®Google Scholar
• Ochoa-Sanchez R, Comai D, and Lacoste B, et al. Promotion of non-rapid eye movement sleep and activation of reticular thalamic neurons by a novel MT2 melatonin receptor ligand. J Neurosci. 2011;31(50):18439–18452.
   PubMed Web of Science ®Google Scholar
• Ochoa-Sanchez R, Rainer Q, and Comai S, et al. Anxiolytic effects of the melatonin MT2 receptor partial agonist UCM765: comparison with melatonin and diazepam. Prog Neuropsychopharmacol Biol Psychiatry. 2012;39(2):318–325.
   PubMed Web of Science ®Google Scholar
• Ferlenghi F, Mari M, Gobbi G, et al. N-(anilinoethyl)amide melatonergic ligands with improved water solubility and metabolic Stability. ChemMedChem. 2021;16(19):3071–3082.
   PubMed Web of Science ®Google Scholar
• Rivara S, Vacondio F, Fioni A, et al. N-(anilinoethyl)amides: design and synthesis of metabolically stable, selective melatonin receptor ligands. ChemMedChem. 2009;4(10):1746–1755.
   PubMed Web of Science ®Google Scholar
• Posa L, De Gregorio D, and Gobbi G, et al. Targeting melatonin MT2 receptors: a novel pharmacological avenue for inflammatory and neuropathic pain. Curr Med Chem. 2018;25(32):3866–3882.
   PubMed Web of Science ®Google Scholar
• Posa L, Lopez-Canul M, and Rullo L, et al. Nociceptive responses in melatonin MT2 receptor knockout mice compared to MT1 and double MT1/MT2 receptor knockout mice. J Pineal Res. 2020;69(3):e12671.
   PubMed Web of Science ®Google Scholar
• Spadoni G, Bedini A, and Lucarini S, et al. Highly potent and selective mt 2 melatonin receptor full agonists from conformational analysis of 1-Benzyl--acylaminomethyl-tetrahydroquinolines. J Med Chem. 2015;58(18):7512–7525.
   PubMed Web of Science ®Google Scholar
• Comai S, De Gregorio D, and Posa L, et al. Dysfunction of serotonergic activity and emotional responses across the light-dark cycle in mice lacking melatonin MT2 receptors. J Pineal Res. 2020;69(1):e12653.
   PubMed Web of Science ®Google Scholar
• Elisi GM, Bedini A, Scalvini L, et al. Chiral recognition of flexible melatonin receptor ligands induced by conformational equilibria. Molecules. 2020;25(18):4057.
   Web of Science ®Google Scholar
• Palczewski K, Kumasaka T, and Hori T, et al. Crystal structure of rhodopsin: a G protein-coupled receptor. Science. 2000;289(5480):739–745.
   PubMed Web of Science ®Google Scholar
• Pala D, Lodola A, and Bedini A, et al. Homology models of melatonin receptors: challenges and recent advances. Int J Mol Sci. 2013;14(4):8093–8121.
   PubMed Web of Science ®Google Scholar
• Pala D, Beuming T, and Sherman W, et al. Structure-based virtual screening of MT2 melatonin receptor: influence of template choice and structural refinement J Chem Inf Model . 2013;53(4):821–835.
   PubMed Web of Science ®Google Scholar
• Clément N, Renault N, and Guillaume J-L, et al. Importance of the second extracellular loop for melatonin MT1 receptor function and absence of melatonin binding in GPR50. Br J Pharmacol. 2018;175(16):3281–3297.
   PubMed Web of Science ®Google Scholar
• Okamoto H, Miyauchi H, and Inoue A, et al. Cryo-EM structure of the human MT1-Gi signaling complex. Nat Struct Mol Biol. 2021;28(8):694–701.
   PubMed Web of Science ®Google Scholar
• Yan J-H, Su H-R, and Boutin JA, et al. High-throughput screening assay for new ligands at human melatonin receptors. Acta Pharmacol Sin. 2008;29(12):1515–1521.
   PubMed Web of Science ®Google Scholar
• Boutin JA, Bonnaud A, and Brasseur C, et al. New MT2 melatonin receptor-selective ligands: agonists and partial agonists. Int J Mol Sci. 2017;18(7):1347.
   Web of Science ®Google Scholar
• Legros C, Brasseur C, and Delagrange P, et al. Alternative radioligands for investigating the molecular pharmacology of melatonin receptors. J Pharmacol Exp Ther. 2016;356(3):681–692.
   PubMed Web of Science ®Google Scholar
• Patel N, Huang XP, and Grandner JM, et al. Structure-based discovery of potent and selective melatonin receptor agonists. eLife. 2020;9:e53779.
   PubMed Web of Science ®Google Scholar
• Liu L, and Jockers R. Structure-based virtual screening accelerates GPCR drug discovery. Trends Pharmacol Sci. 2020;41(6):382–384.
   PubMed Web of Science ®Google Scholar
• Karamitri A, and Jockers R. Melatonin in type 2 diabetes mellitus and obesity. Nat Rev Endocrinol. 2019;15(2):105–125.
   PubMed Web of Science ®Google Scholar
• Owino S, Buonfiglio DDC, and Tchio C, et al. Melatonin signaling a key regulator of glucose homeostasis and energy metabolism. Front Endocrinol (Lausanne). 2019;10:488.
   PubMed Web of Science ®Google Scholar
• Gurunathan S, Qasim M, and Kang M-H, et al. Role and therapeutic potential of melatonin in various type of cancers. Onco Targets Ther. 2021;14:2019–2052.
   PubMed Web of Science ®Google Scholar
• Crooke A, Colligris B, and Pintor J. Update in glaucoma medicinal chemistry: emerging evidence for the importance of melatonin analogues. Curr Med Chem. 2012;19(21):3508–3522.
   PubMed Web of Science ®Google Scholar
• Scuderi L, Davinelli S, and Iodice CM, et al. Melatonin: implications for ocular disease and therapeutic potential. Curr Pharm Des. 2019;25(39):4185–4191.
   PubMed Web of Science ®Google Scholar
• Posa L, De Gregorio D, Gobbi G et al. Targeting Melatonin MT2 Receptors: A Novel Pharmacological Avenue for Inflammatory and Neuropathic Pain. Curr Med Chem. 2018;25(32):3866–3882.
   PubMed Web of Science ®Google Scholar
• Kinker GS, Ostrowski LH, and Ribeiro PAC, et al. MT1 and MT2 melatonin receptors play opposite roles in brain cancer progression. J Mol Med (Berl). 2021;99(2):289–301.
   PubMed Web of Science ®Google Scholar
• Oertel J, Golz L, and Kirch W. Elucidation of Neu-P11 metabolism in urine of volunteers by liquid chromatography-tandem mass spectrometry. J Chromatogr A. 2013;1278:69–75.
   PubMed Web of Science ®Google Scholar
• Zemlan FP, Mulchahey JJ, and Scharf MB, et al. The efficacy and safety of the melatonin agonist beta-methyl-6-chloromelatonin in primary insomnia: a randomized, placebo-controlled, crossover clinical trial. J Clin Psychiatry. 2005;66(3):384–390.
   PubMed Web of Science ®Google Scholar
• Journé A-S, Habib SAM, Dodda BR, et al. N1-linked melatonin dimers as bivalent ligands targeting dimeric melatonin receptors. MedChemComm. 2014;5:792–796.
   Web of Science ®Google Scholar
• Karamitri A, Sadek MS, and Journé A-S, et al. O-linked melatonin dimers as bivalent ligands targeting dimeric melatonin receptors. Eur J Med Chem. 2019;85:349–356.
   Google Scholar
• Oishi A, Cecon E, and Jockers R. Melatonin receptor signaling: impact of receptor oligomerization on receptor function. Int Rev Cell Mol Biol. 2018;38:59–77.
   Google Scholar
• Legros C, Devavry S, and Caignard S, et al. Melatonin MT₁ and MT₂ receptors display different molecular pharmacologies only in the G-protein coupled state. Br J Pharmacol. 2014;171(1):186–201.
   PubMed Web of Science ®Google Scholar
• Elisi GM, Scalvini L, and Lodola A, et al. Free-energy simulations support a lipophilic binding route for melatonin receptors. J Chem Inf Model. 2022;62(1):210–222.
   PubMedGoogle Scholar
• De Bodinat C, Guardiola-Lemaître B, and Mocaër E, et al. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov. 2010;9(8):628–642.
   PubMed Web of Science ®Google Scholar
• Gerbier R, Ndiaye-Lobry D, and Martínez de Morentin PB, et al. Pharmacological evidence for transactivation within melatonin MT2 and serotonin 5-HT2C receptor heteromers in mouse brain. FASEB J. 2021;35(1):e21161.
   PubMed Web of Science ®Google Scholar
• Hasan M, Marzouk MA, and Adhikari S, et al. Pharmacological, mechanistic, and pharmacokinetic assessment of novel melatonin-tamoxifen drug conjugates as breast cancer drugs. Mol Pharmacol. 2019;96(2):272–296.
   PubMed Web of Science ®Google Scholar
• Spadoni G, Bedini A, and Furiassi L, et al. Identification of bivalent ligands with melatonin receptor agonist and fatty acid amide hydrolase (FAAH) inhibitory activity that exhibit ocular hypotensive effect in the rabbit. J Med Chem. 2018;61(17):7902–7916.
   PubMed Web of Science ®Google Scholar